Your Genetic Make Up to be Stored, Without Consent, for Profit
By TechEye,
TechEye
| 04. 25. 2013
Dr Helen Wallace, director of GeneWatch UK, warned at a MedConfidential event in London that beyond electronically storing patient records, the next step for the UK is linking these records with DNA and genetic information on an all-in-one database.
It is already public policy, she pointed out, and a Human Genomics Strategy Group (HGSG) urged the need for a national DNA database for personalised medicine last year - which was welcomed by the secretary of state for health, which has asked for the recommendations to be implemented.
Genetic data is massively revealing - and can be used to identify relatives as well as the patient, and can be used to assess the potential for passing recessive genetic disorders on to children.
Anonymisation here, Wallace argued, is impossible. For example, it would be possible to swab DNA from a coffee cup and compare this to your sequence, also linked to your medical record, stored in a research database. The HGSG plan threatens to remove people's right to know exactly who is using their genomic data and why - as...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...